SAN DIEGO--(BUSINESS WIRE)--KFx Medical Corporation today announced that it was granted a new patent from the United States Patent and Trademark Office: U.S. Patent No. 8,100,942 broadly covering knotless double row rotator cuff repair. The new patent bolsters KFx Medicals patent portfolio and highlights KFx Medicals innovation in the orthopaedic and medical devices industry.

In 2011, an anonymous party filed a request that the Patent Office re-examine KFxs first and seminal patent (U.S. Pat. No. 7,585,311) which also broadly covers knotless double row rotator cuff repair. The Patent Office rejected all arguments made by the anonymous party and completely upheld the KFx patent.

"This new patent further increases the value and importance of KFx Medicals patent portfolio for the clinically important area of knotless double row rotator cuff repair," indicated Tate Scott, KFx Medical president and CEO. "Our patent counsel, Knobbe Martens, has done an excellent job in executing our strategy to protect the inventions as described in our patent estate. With each patent, we demonstrate our ongoing commitment to innovation in orthopaedic surgery so that our investors and employees may be rewarded for their contributions."

The new AppianFx line of implants from KFx are used to reattach tissue to and in bone during shoulder, knee, foot and ankle procedures which combined exceed well over 1 million annual surgical procedures in the United States. Product offerings include those that directly place and secure tissue into bone both with and without the use of sutures.

For additional information about KFx Medical Corporation, visit

About KFx Medical Corporation

Headquartered in Carlsbad, Calif., KFx Medical Corporation was founded in 2003 to develop tissue fixation and bone implant products used in a variety of orthopedic surgical procedures performed on the shoulder, knee, foot, and ankle. KFx provides simple solutions for orthopedic surgeons specializing in sports medicine. The company is privately held - investors include Alloy Ventures , Charter Life Sciences , Arboretum Ventures, Montreux Equity Partners, and MB Venture Partners.

Posted by Sean Fenske, Editor-in-Chief, MDT